ProPhase Labs' Revenue Plummets Amid Diagnostic Business Exit

Ticker: PRPH · Form: 10-Q · Filed: Nov 19, 2025 · CIK: 868278

Prophase Labs, INC. 10-Q Filing Summary
FieldDetail
CompanyProphase Labs, INC. (PRPH)
Form Type10-Q
Filed DateNov 19, 2025
Risk Levelhigh
Pages16
Reading Time19 min
Key Dollar Amounts$0.0005
Sentimentbearish

Sentiment: bearish

Topics: Biotech, Genomics, Diagnostics, Financial Performance, Regulatory Risk, Strategic Pivot, Liquidity

TL;DR

**PRPH is bleeding cash and making a risky pivot from COVID testing to unproven genomics and biopharma; steer clear until they show a clear path to profitability.**

AI Summary

ProPhase Labs, Inc. (PRPH) reported a net loss of $6.839 million for the three months ended September 30, 2025, compared to a net loss of $6.587 million in the prior-year period. Revenues significantly declined to $883,000 for the quarter, down from $1.416 million in Q3 2024, and for the nine months, revenues were $3.561 million, a substantial drop from $5.276 million in the same period of 2024. The company's gross profit turned negative, reporting a loss of $123,000 for the quarter, compared to a profit of $215,000 in Q3 2024. A key business change includes the cessation of COVID-19 diagnostic testing by its subsidiaries ProPhase Diagnostics, Inc., ProPhase Diagnostics NY, Inc., and ProPhase Diagnostics NJ, Inc. in May 2025, leading to a Chapter 11 reorganization filing for these entities to pursue unpaid insurance claims. Strategic outlook focuses on growing its genomics businesses, Nebula Genomics and DNA Complete, and commercializing the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test, with commercialization planned for Q1 2026. Risks include dependence on the success of novel drug development, market adoption rates for new products, and potential future regulatory changes for Laboratory Developed Tests (LDTs).

Why It Matters

ProPhase Labs' significant revenue decline and shift away from COVID-19 diagnostics signal a critical pivot for investors. The company is betting on its genomics and biopharma segments, particularly the BE-Smart test, to drive future growth. For employees, this means a focus on new scientific and commercial roles within genomics and biopharma, while customers will see new diagnostic and wellness products. The broader market will watch if PRPH can successfully transition from a pandemic-driven business to a sustainable biotech player, especially given the competitive landscape in genomics and cancer diagnostics.

Risk Assessment

Risk Level: high — The company reported a net loss of $6.839 million for Q3 2025 and $7.345 million for the nine months ended September 30, 2025, coupled with a negative gross profit of $123,000 for the quarter. Cash and cash equivalents decreased from $678,000 at December 31, 2024, to $405,000 at September 30, 2025, indicating significant liquidity challenges and reliance on financing activities.

Analyst Insight

Investors should exercise extreme caution and consider avoiding PRPH shares until there is clear evidence of successful commercialization and profitability from its genomics and biopharma ventures. Monitor the progress of the BE-Smart test and the outcome of the Chapter 11 proceedings for the diagnostic subsidiaries.

Financial Highlights

debt To Equity
8.58
revenue
$883,000
operating Margin
N/A
total Assets
$65.702 million
total Debt
$58.841 million
net Income
($6.839 million)
eps
N/A
gross Margin
-13.9%
cash Position
$405,000
revenue Growth
-37.6%

Revenue Breakdown

SegmentRevenueGrowth
Diagnostic Testing Services$883,000-37.6%

Key Numbers

Key Players & Entities

FAQ

What caused ProPhase Labs' revenue decline in Q3 2025?

ProPhase Labs' revenue decline in Q3 2025 was primarily caused by the cessation of COVID-19 diagnostic testing by its subsidiaries in May 2025, leading to a significant drop in diagnostic service revenue. Net revenues fell to $883,000 for the quarter, down from $1.416 million in Q3 2024.

What is the strategic outlook for ProPhase Labs' genomics business?

ProPhase Labs is focused on growing its genomics businesses, Nebula Genomics and DNA Complete, which offer whole genome sequencing and related services. DNA Complete plans to sell direct-to-consumers online, in retail stores, and provide testing for university research.

What is the status of the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test?

The BE-Smart test successfully completed a key validation study in June 2025, demonstrating over 95% technical success. ProPhase Labs plans commercialization as a Laboratory Developed Test (LDT) and Research Use Only (RUO) product in Q1 2026, with broader insurance-backed commercialization targeted for Q3 2026.

What are the key risks associated with ProPhase Labs' current strategy?

Key risks include the high dependence on the successful development and market adoption of novel drugs and compounds like Equivir and Linebacker, as well as the BE-Smart test. Future legislative or regulatory actions could also alter the framework for LDTs, potentially delaying market entry or increasing costs.

How has the FDA's stance on Laboratory Developed Tests (LDTs) impacted ProPhase Labs?

The U.S. District Court for the Eastern District of Texas vacated the FDA's Final Rule that would have expanded FDA oversight of LDTs in March 2025, and the FDA formally rescinded the rule in August 2025. This means LDTs, including BE-Smart, are not currently subject to direct FDA oversight, potentially allowing for faster market entry under CLIA framework.

What is ProPhase Labs doing about its unpaid insurance claims from diagnostic testing?

ProPhase Labs' diagnostic subsidiaries (ProPhase Diagnostics, Inc., ProPhase Diagnostics NY, Inc., and ProPhase Diagnostics NJ, Inc.) filed for Chapter 11 reorganization in September 2025. This action, guided by legal advisor Crown Medical Collections, aims to streamline and accelerate the recovery of tens of millions of dollars in unpaid insurance claims.

How did ProPhase Labs' cash position change in the first nine months of 2025?

ProPhase Labs experienced a decrease in cash and cash equivalents of $273,000 during the nine months ended September 30, 2025, bringing the total to $405,000. This was driven by $7.114 million in cash used in operating activities, partially offset by $920,000 from investing activities and $5.921 million from financing activities.

What is ProPhase Labs' intellectual property position for the BE-Smart test?

ProPhase Labs owns the full intellectual property portfolio for the BE-Smart test, including a foundational patent family covering molecular markers of esophageal disease progression. U.S. Patent No. 12,379,378 B2 was issued on August 6, 2025, with patents and pending applications expected to provide protection until 2040.

What are the implications of the increase in ProPhase Labs' current liabilities?

ProPhase Labs' total current liabilities increased significantly to $55.287 million at September 30, 2025, from $32.134 million at December 31, 2024. This increase is largely due to $27.653 million in accounts payable to unconsolidated affiliates and the introduction of new short-term convertible notes payable and derivative liabilities, indicating increased financial obligations.

What should investors consider regarding ProPhase Labs' stock dilution?

Investors should note that ProPhase Labs' common shares outstanding increased from 29,874,029 at December 31, 2024, to 41,541,205 at September 30, 2025. This 39% increase in shares outstanding, primarily from the issuance of common shares for cash, indicates dilution for existing shareholders.

Risk Factors

Industry Context

The diagnostics and genomics sectors are characterized by rapid technological advancement and evolving regulatory landscapes. ProPhase Labs is navigating this by pivoting from COVID-19 testing, which saw a boom and subsequent decline, towards genomics and novel diagnostic screening. Success hinges on innovation, market adoption of new technologies like the BE-Smart test, and managing the complexities of Laboratory Developed Tests (LDTs).

Regulatory Implications

The company faces potential regulatory shifts, particularly concerning Laboratory Developed Tests (LDTs), as it expands its focus into genomics and diagnostics. The Chapter 11 filings for its diagnostic subsidiaries also highlight operational and financial compliance challenges within the healthcare services sector.

What Investors Should Do

  1. Monitor BE-Smart commercialization progress and market adoption.
  2. Analyze the financial health and recovery prospects of diagnostic subsidiaries.
  3. Evaluate the performance and risks associated with investments in unconsolidated affiliates.
  4. Assess the impact of increased liabilities and reduced cash on operational flexibility.
  5. Track share count changes and potential dilution.

Key Dates

Glossary

Unconsolidated Affiliates
Investments in other companies where ProPhase Labs has significant influence but does not have control, meaning they are not fully consolidated into the company's financial statements. (The company made a substantial new investment of $43.657 million in these entities, which also led to significant related party payables, indicating a strategic shift and potential financial entanglements.)
Chapter 11 Reorganization
A form of bankruptcy that allows a business to reorganize its debts and operations while continuing to function, typically to allow for recovery of assets or claims. (The diagnostic subsidiaries filed for Chapter 11 to pursue unpaid insurance claims, highlighting operational challenges and a need to restructure their financial recovery efforts.)
Laboratory Developed Tests (LDTs)
Diagnostic tests developed and performed within a single laboratory, often subject to evolving regulatory oversight. (The company's strategic shift towards genomics and diagnostics means it may face increased scrutiny or changes in regulations governing LDTs.)
Accumulated Deficit
The cumulative net losses of a company over its lifetime that have not been offset by net income. (The company has a significant accumulated deficit of ($65.738 million) as of September 30, 2025, reflecting its history of net losses.)
Derivative Liability
A financial instrument whose value is derived from an underlying asset, which can create a liability for the company. (The appearance of a $2.688 million derivative liability in current liabilities suggests new complex financial instruments or hedging activities.)

Year-Over-Year Comparison

ProPhase Labs reported a significant downturn in its most recent filing compared to the prior year. Revenue for Q3 2025 plummeted by 37.6% to $883,000 from $1.416 million in Q3 2024, and gross profit turned negative at ($123,000) versus a profit of $215,000. While the net loss for the nine months decreased substantially from $19.005 million to $7.345 million, this was largely due to a gain from discontinued operations, not operational improvement. Key risks have shifted, with the cessation of diagnostic testing operations and associated Chapter 11 filings becoming prominent, alongside increased liabilities and a reduced cash position.

Filing Stats: 4,692 words · 19 min read · ~16 pages · Grade level 16.5 · Accepted 2025-11-19 16:06:08

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 39 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 49 Item 4.

Controls and Procedures

Controls and Procedures 49

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 51 Item 1A.

Risk Factors

Risk Factors 51 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 53 Item 3. Defaults Upon Senior Securities 54 Item 4. Mine Safety Disclosures 54 Item 5. Other Information 54 Item 6. Exhibits 54

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. ProPhase Labs, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 405 $ 678 Accounts receivable, net 3,284 20,058 Inventory, net 266 1,143 Prepaid expenses and other current assets 3,818 2,615 Current assets in discontinued operations — 6,143 Total current assets 7,773 30,637 Property, plant and equipment, net 2,349 7,501 Investment in unconsolidated affiliates 43,657 — Prepaid expenses, net of current portion 140 217 Operating lease right-of-use asset, net — 4,115 Intangible assets, net 7,813 9,750 Goodwill 3,968 5,231 Other assets 2 310 Non-current assets in discontinued operations — 5,439 TOTAL ASSETS $ 65,702 $ 63,200 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 14,195 $ 13,717 Accounts payable to unconsolidated affiliates 27,653 — Accrued diagnostic services — 31 Accrued advertising and other allowances 151 151 Finance lease liabilities 2,580 2,147 Operating lease liabilities — 1,214 Short-term loan payable, net of discount of $ 629 and $ 237 3,185 3,207 Short-term loan payable to related party, net of discount of $ 188 437 — Short-term convertible notes payable, net of discount of 3,233 517 — Derivative liability 2,688 — Deferred revenue 1,374 1,698 Income tax payable 291 1,987 Other current liabilities 2,216 2,115 Current liabilities in discontinued operations — 5,867 Total current liabilities 55,287 32,134 Non-current liabilities: 3 Unsecured promissory notes, net of discount of $ 127 — 9,873 Unsecured long-term debt, net of discount of $ — and $ 423 — 1,779 Due to sellers (see Note 3) 2,000 2,000 Deferred revenue, net of current portion 589 784 Operating lease liabilities, net of current portion — 3,762 Finance lease liabilities, net of current portion 965 2,591 Non-current liabiliti

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing